OYE Therapeutics

11:30 AM - 11:45 AM (EST), Tuesday, February 7, 2023 ・ Palace
Sole source branded drug product development program ready to enter the clinic.

Platform is a first to market to address three unmet medical needs with a $60B TAM worldwide.

Lead candidate is 36 Months to FDA approval via a single Phase 3 study and 505(b)2 regulatory pathway. Therapeutic area reverses general anesthesia solving complications at anesthesia emergence, SAM $2.2B USA.

The second vertical is a dual use (Military/civilian) drug product. Funded thru Phase 2 with $10M non-dilutive congressional appropriation and sole source supply agreement with US Dept of Defense. Commercial use, reversal of opioid induced respiratory depression without reversing analgesic, has 27M annual prescribing opportunities in hospital recovery rooms and on the floors.

Program 3 reverses sedative-hypnotic toxidrome. Phase 2a/2b clinical start.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Prepared to inject 1st patient
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CEO and Founder
OYE Therapeutics, Inc.